Skip to ContentSkip to Navigation
About us Latest news News News articles

A virosomal respiratory syncytial virus vaccine candidate with a Toll-like receptor ligand as built-in adjuvant. Preclinical evaluation of immunogenicity, efficacy and safety

07 November 2012

PhD ceremony: Mr. T. Kamphuis, 11.00 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: A virosomal respiratory syncytial virus vaccine candidate with a Toll-like receptor ligand as built-in adjuvant. Preclinical evaluation of immunogenicity, efficacy and safety

Promotor(s): prof. J.C. Wilschut

Faculty: Medical Sciences

Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants and young children. Infection with RSV also causes significant morbidity and mortality in elderly people. A vaccine against RSV would significantly reduce the health burden caused by RSV infection.

In this study, we evaluated a virosomal RSV vaccine. A virosome is a virus particle without the genetic material. It does contain the surface proteins causing the immune response after vaccination. A virosome therefore is similar to a virus particle for the immune system, but is incapable of replication and therefore cannot cause disease. To improve the immune response induced by the virosomes, we included a so-called TLR ligand in the virosomal structure. Inclusion of this TLR ligand stimulates and skews the immune response. It has a positive influence on both safety and efficacy of the vaccine. In this study, we showed that is it feasible to produce RSV virosomes with a built-in TLR ligand. We subsequently tested this vaccine candidate in animal models. These tests showed the vaccine to be immunogenic and safe when administered to animals. Vaccinated animals were protected against infection with live virus.

Last modified:13 March 2020 12.58 a.m.
View this page in: Nederlands

More news

  • 27 March 2024

    UG/UMCG researchers receive prestigious research grant

    RUG/UMCG scientists Mark Hipp, Bart Eggen, Moniek Tromp and Marleen Kamperman, along with colleagues, are involved in four of seven Dutch science consortia.

  • 26 March 2024

    Preventing the next depression

    Marie-José van Tol, Professor of 'Mood and Cognition’, studies what people who are prone to depression can do themselves in order to prevent recurrence.

  • 18 March 2024

    VentureLab North helps researchers to develop succesful startups

    It has happened to many researchers. While working, you suddenly ask yourself: would this not be incredibly useful for people outside of my own research discipline? There are many ways to share the results of your research. For example, think of a...